Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Rad51 promoter-targeted gene therapy is effective for in vivo visualization and treatment of cancer.

Hine CM, Seluanov A, Gorbunova V.

Mol Ther. 2012 Feb;20(2):347-55. doi: 10.1038/mt.2011.215. Epub 2011 Oct 18.

2.

Use of the Rad51 promoter for targeted anti-cancer therapy.

Hine CM, Seluanov A, Gorbunova V.

Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20810-5. doi: 10.1073/pnas.0807990106. Epub 2008 Dec 23.

4.

Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin.

Ito M, Yamamoto S, Nimura K, Hiraoka K, Tamai K, Kaneda Y.

J Gene Med. 2005 Aug;7(8):1044-52.

PMID:
15756713
5.

A polymer library approach to suicide gene therapy for cancer.

Anderson DG, Peng W, Akinc A, Hossain N, Kohn A, Padera R, Langer R, Sawicki JA.

Proc Natl Acad Sci U S A. 2004 Nov 9;101(45):16028-33. Epub 2004 Nov 1.

6.

In vivo bioluminescence imaging of murine xenograft cancer models with a red-shifted thermostable luciferase.

Mezzanotte L, Fazzina R, Michelini E, Tonelli R, Pession A, Branchini B, Roda A.

Mol Imaging Biol. 2010 Aug;12(4):406-14. doi: 10.1007/s11307-009-0291-3. Epub 2009 Nov 25.

PMID:
19937390
7.

Development of targeted therapy for ovarian cancer mediated by a plasmid expressing diphtheria toxin under the control of H19 regulatory sequences.

Mizrahi A, Czerniak A, Levy T, Amiur S, Gallula J, Matouk I, Abu-lail R, Sorin V, Birman T, de Groot N, Hochberg A, Ohana P.

J Transl Med. 2009 Aug 6;7:69. doi: 10.1186/1479-5876-7-69.

8.

A nanoparticle formulation that selectively transfects metastatic tumors in mice.

Yang J, Hendricks W, Liu G, McCaffery JM, Kinzler KW, Huso DL, Vogelstein B, Zhou S.

Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):14717-22. doi: 10.1073/pnas.1313330110. Epub 2013 Aug 19.

9.

Efficient inhibition of ovarian cancer by recombinant CXC chemokine ligand 10 delivered by novel biodegradable cationic heparin-polyethyleneimine nanogels.

Yang F, Gou M, Deng H, Yi T, Zhong Q, Wei Y, Zhao X.

Oncol Rep. 2012 Aug;28(2):668-76. doi: 10.3892/or.2012.1853. Epub 2012 Jun 6.

PMID:
22684947
11.

A bioluminescent transposon reporter-trap identifies tumor-specific microenvironment-induced promoters in Salmonella for conditional bacterial-based tumor therapy.

Flentie K, Kocher B, Gammon ST, Novack DV, McKinney JS, Piwnica-Worms D.

Cancer Discov. 2012 Jul;2(7):624-37. doi: 10.1158/2159-8290.CD-11-0201. Epub 2012 May 3.

12.
13.
14.

Low generation PAMAM dendrimer and CpG free plasmids allow targeted and extended transgene expression in tumors after systemic delivery.

Navarro G, Maiwald G, Haase R, Rogach AL, Wagner E, de Ilarduya CT, Ogris M.

J Control Release. 2010 Aug 17;146(1):99-105. doi: 10.1016/j.jconrel.2010.04.030. Epub 2010 May 11.

PMID:
20438778
15.

Adenoviral vector driven by a minimal Rad51 promoter is selective for p53-deficient tumor cells.

Fong V, Osterbur M, Capella C, Kim YE, Hine C, Gorbunova V, Seluanov A, Dewhurst S.

PLoS One. 2011;6(12):e28714. doi: 10.1371/journal.pone.0028714. Epub 2011 Dec 9.

16.

Adenovirus-mediated tissue-targeted expression of the CDglyTk gene for the treatment of breast cancer.

Su GQ, Su G, Huang ZH.

Mol Med Rep. 2012 Aug;6(2):321-9. doi: 10.3892/mmr.2012.925. Epub 2012 May 23.

PMID:
22641384
17.

Blood-based screening and light based imaging for the early detection and monitoring of ovarian cancer xenografts.

Chaudhuri TR, Cao Z, Krasnykh VN, Stargel AV, Belousova N, Partridge EE, Zinn KR.

Technol Cancer Res Treat. 2003 Apr;2(2):171-80.

PMID:
12680799
18.

Quantitative analysis of p53-targeted gene expression and visualization of p53 transcriptional activity following intratumoral administration of adenoviral p53 in vivo.

Ohtani S, Kagawa S, Tango Y, Umeoka T, Tokunaga N, Tsunemitsu Y, Roth JA, Taya Y, Tanaka N, Fujiwara T.

Mol Cancer Ther. 2004 Jan;3(1):93-100.

19.

Utilization of Rad51C promoter for transcriptional targeting of cancer cells.

Cao Y, Xu Y, Zhang L, Li Z, Jiang Y, Tian X, Seluanov A, Gorbunova V, Mao Z.

Oncotarget. 2014 Apr 15;5(7):1805-11.

20.

Targeted expression of BikDD eliminates breast cancer with virtually no toxicity in noninvasive imaging models.

Xie X, Li L, Xiao X, Guo J, Kong Y, Wu M, Liu W, Gao G, Hsu JL, Wei W, Hung MC, Xie X.

Mol Cancer Ther. 2012 Sep;11(9):1915-24. doi: 10.1158/1535-7163.MCT-12-0191. Epub 2012 Jul 2.

Items per page

Supplemental Content

Write to the Help Desk